(Q34651253)

3 August 2017

1 reference

title

Lipid posttranslational modifications. Farnesyl transferase inhibitors (English)

1 reference

3 August 2017

Andrea D Basso

1

1 reference

PubMed ID

16278491

3 August 2017

Paul Kirschmeier

series ordinal

2

1 reference

PubMed ID

16278491

3 August 2017

W Robert Bishop

series ordinal

3

1 reference

3 August 2017

8 November 2005

1 reference

Journal of Lipid Research

3 August 2017

1 reference

3 August 2017

47

1 reference

3 August 2017

15-31

1 reference

3 August 2017

1

1 reference

Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase

3 August 2017

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

p21ras is modified by a farnesyl isoprenoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Mechanism of digeranylgeranylation of Rab proteins. Formation of a complex between monogeranylgeranyl-Rab and Rab escort protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Protein farnesyltransferase and geranylgeranyltransferase share a common alpha subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Protein farnesyltransferase: kinetics of farnesyl pyrophosphate binding and product release

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The crystal structure of human protein farnesyltransferase reveals the basis for inhibition by CaaX tetrapeptides and their mimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Cocrystal structure of protein farnesyltransferase complexed with a farnesyl diphosphate substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Identification of Ras farnesyltransferase inhibitors by microbial screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Synergy between anions and farnesyldiphosphate competitive inhibitors of farnesyl:protein transferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

High-performance liquid chromatography/mass spectrometry characterization of Ki4B-Ras in PSN-1 cells treated with the prenyltransferase inhibitor L-778,123.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Altered growth of human colon cancer cell lines disrupted at activated Ki-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Activation of Raf as a result of recruitment to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Purification of a murine protein-tyrosine/threonine kinase that phosphorylates and activates the Erk-1 gene product: relationship to the fission yeast byr1 gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Fluorimetric evaluation of the affinities of isoprenylated peptides for lipid bilayers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Fatty acylation and prenylation of proteins: what's hot in fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Inhibition of DNA synthesis by a farnesyltransferase inhibitor involves inhibition of the p70(s6k) pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A novel approach for expression cloning of small GTPases: identification, tissue distribution and chromosome mapping of the human homolog of rheb

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Regulation of TSC2 by 14-3-3 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Akt regulates growth by directly phosphorylating Tsc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The LKB1 tumor suppressor negatively regulates mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Rheb binds and regulates the mTOR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Drosophila Rheb GTPase is required for cell cycle progression and cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Rheb promotes cell growth as a component of the insulin/TOR signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Rheb is an essential regulator of S6K in controlling cell growth in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The microtubule-dependent motor centromere-associated protein E (CENP-E) is an integral component of kinetochore corona fibers that link centromeres to spindle microtubules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

CENP-E is a plus end-directed kinetochore motor required for metaphase chromosome alignment

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

CENP-F is a protein of the nuclear matrix that assembles onto kinetochores at late G2 and is rapidly degraded after mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Mammalian cytosolic DnaJ homologues affect the hsp70 chaperone-substrate reaction cycle, but do not interact directly with nascent or newly synthesized proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

YDJ1p facilitates polypeptide translocation across different intracellular membranes by a conserved mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The human DnaJ homologue dj2 facilitates mitochondrial protein import and luciferase refolding

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A role for HDJ-2/HSDJ in correcting subnuclear trafficking, transactivation, and transrepression defects of a glucocorticoid receptor zinc finger mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Lamin activity is essential for nuclear envelope assembly in a Drosophila embryo cell-free extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Isoprenylation is required for the processing of the lamin A precursor

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Maturation of nuclear lamin A involves a specific carboxy-terminal trimming, which removes the polyisoprenylation site from the precursor; implications for the structure of the nuclear lamina

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Prelamin A endoproteolytic processing in vitro by recombinant Zmpste24

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Prenylated prelamin A interacts with Narf, a novel nuclear protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Lamin a truncation in Hutchinson-Gilford progeria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Investigation of the effect of the farnesyl protein transferase inhibitor R115777 on isoprenylation and intracellular signalling by the prostacyclin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

New targets for therapy in breast cancer: farnesyltransferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

The nuclear lamina is a meshwork of intermediate-type filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.R500012-JLR200

10.1194/JLR.R500012-JLR200

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

16278491